SIDE EFFECTS OF MENECTRA

Menactra is indicated for active immunization to prevent invasive meningococcal

disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra is
approved for use in individuals 9 months through 55 years of age. Menactra does not
prevent N meningitidis serogroup B disease.
• Meningococcus has been grouped into at least 13 different groups
based on serological differences in the surface polysaccharides.
• Of these, five serogroups—A, B, C, W-135, and Y—are responsible for
almost all instances of meningococcal disease 
Expected side effects

• Injection site pain,induration,erythema (40%)

• Headache
• Fatigue
• Adverse Effects
Anaphylaxsis (Epinephrine)
Febrile seizures
GBS ?
A 36y/female presented to ER on 15/07/2019 with chief complaints
• Headache with neck pain
• Fever with body pains
• Giddiness
• Severe nausea with vomintings..1-2 episodes/day
• ? Blurring of vision
H/O Present Illness :-Patient apparently asymptomatic til 13/07/19,had
developed above complaints since ~5 p.m 13/07/19.
Patient had taken MENACTRA(meningococcal vaccine) at ~10 a.m same
day..post vaccination started to have symptoms.
No h/0 allergy to protiens or latex documented in past.
Husband of the patient presented similar complaints with mild severeity.
• Patient remained stable,symptomatically improved with no further
vomitings or giddiness.patient is discharged after 24 hrs in a
hemodynamically stable condition.
• Pateint non diabetic ,non hypertensive
• Vitals at admission
Pulse rate:110/min
Blood Pressure: 100/70 mmhg
Spo2 :95% on Room Air
CVS: NAD
RS : Mild whezze B/L
CNS: Pupils –NSRL
CN-NAD
SENSORY-NAD
P/A :NAD
• Investigations
CBP ~N
Na-140,K-3.9,cl-104

• summary
Patient was admitted in ward, treatment given with IV fluids,Anti emetics,PPI,ORAL Paracetamol.
 Studies Contributing to
Epidemiologic the Epidemiologic Cases Contributing to the
Vaccine Adverse Event Assessment Assessment Mechanistic Assessment Mechanistic Assessment Causality Conclusion
Meningococcal Encephalitis Limited 1 Lacking None Inadequate

Meningococcal Encephalopathy Limited 1 Lacking None Inadequate

Meningococcal Acute Disseminated Insufficient None Lacking None Inadequate

Encephalomyelitis

Meningococcal Transverse Myelitis Insufficient None Lacking None Inadequate

Meningococcal Multiple Sclerosis Insufficient None Lacking None Inadequate

Meningococcal Guillain-Barré Syndrome Limited 1 Lacking None Inadequate

Meningococcal Chronic Inflammatory Insufficient None Lacking None Inadequate

Disseminated
Polyneuropathy

Meningococcal Anaphylaxis Insufficient None Strong 1 Convincingly Supports

Meningococcal Chronic Headache Insufficient None Lacking None Inadequate

 PATIENT COUNSELING INFORMATION
• Vaccine Information Statements are required by the National
Childhood Vaccine Injury Act of 1986 to be given prior to
immunization to the patient, parent, or guardian.
Inform the patients, parents or guardians about:
• • Potential benefits and risks of immunization with Menactra.
• • Potential for adverse reactions that have been temporally
associated with administration of Menactra or other vaccines
containing similar components.
• • Reporting any adverse reactions to their healthcare provider.
THANK YOU